Zyprexa shot gets panel's OK

A few hours of extreme drowsiness is not a bad trade-off for schizophrenia patients who have problems sticking to their medication. So said an FDA advisory committee yesterday in backing approval of Eli Lilly's new long-acting, injectable form of Zyprexa.

The advisory panel said that Zyprexa LAI was "acceptably safe" for use in patients with a history of not taking their meds. That's despite the fact that it caused "profound sedation" in some--so severe, in a few cases, that patients lost consciousness or fell into a coma. The sedative effect was seen in 24 of 2,045 patients studied.

Lilly is proposing a risk-management program under which patients would be observed for an hour after receiving the injection, and would be instructed to have friends or family members monitor them for another two hours so they could get medical attention if necessary.

This long-acting form of Zyprexa also causes weight gain, changes in blood sugar, and high cholesterol--the same side effects seen in the oral form.

- see Lilly's release
- read the report from CNN Money

Related Articles:
Lilly settlement leaked in errant email. Report
Shareholders sue Lilly over Zyprexa. Report
Lilly could pay $1B to settle on Zyprexa. Report
Zyprexa--Top 10 Warnings and Recalls of 2007. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.